# Ionis Pharmaceuticals Stock Plunges After Q3 Earnings

> Ionis Pharmaceuticals stock drops 25% following Q3 earnings that missed Tryngolza sales targets.
- Title: Ionis Pharmaceuticals Stock Plunges After Q3 Earnings
- Summary: Ionis Pharmaceuticals stock drops 25% following Q3 earnings that missed Tryngolza sales targets.
- Keywords: ionis pharmaceuticals, tryngolza, q3 earnings, stock plunge, sales guidance, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4965298-ionis-pharmaceuticals-q3-triggers-latest-selloff-on-tryngolza-disappointment
- Published: 2026-11-09T22:35:44+00:00
- Read time: 1 min
- Topics: ionis pharmaceuticals, tryngolza, q3 earnings, stock plunge, sales guidance, money, business
## Q3 Earnings Impact
Ionis Pharmaceuticals stock plunged over 25% after Q3 earnings despite beating revenue and EPS expectations.
## Sales Guidance Cut
IONS slashed 2026 Tryngolza sales guidance by more than half due to slower uptake and competitive pressures.
## Confidence Erosion
Major clinical and commercial setbacks in 2026 have eroded confidence in IONS' transition to mainstream biopharma.
## Key takeaway

Ionis Pharmaceuticals stock fell 25% after Q3 earnings showed slower-than-expected Tryngolza uptake and competitive pressures.